0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD69

CD69

CD69 Molecule Information

Name:DNA (cytosine-5)-methyltransferase 1
Target Synonym:DNMT,DNA (Cytosine-5)-Methyltransferase 1,EC 2.1.1.37,ADCADN,HSN1E,Dnmt1,AIM,MCMT,DNA methyltransferase HsaI,DNA Methyltransferase 1,CXXC-Type Zinc Finger Protein 9,DNA MTase HsaI,M.HsaI,CXXC9,EC:2.1.1.37,DNA (Cytosine-5-)-Methyltransferase 1
Number of Launched Drugs:5
Number of Drugs in Clinical Trials:7
Lastest Research Phase:Approved

CD69 Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
CD9-H5222 Human Human CD69 / CLEC2C Protein, His Tag
CD9-H5222-structure
CD9-H5222-sds

CD69 Molecule Synonym Name

CD69,CLEC2C,AIM,BL-AC/P26,EA1,GP32/28,MLR-3

CD69 Molecule Background

Early activation antigen CD69 is also known as C-type lectin domain family 2 member C (CLEC2C), Activation inducer molecule (AIM), Early T-cell activation antigen p60, Leukocyte surface antigen Leu-23. CD69 contains one C-type lectin domain. CD69 / CLEC2C is expressed on the surface of activated T-cells, B-cells, natural killer cells, neutrophils, eosinophils, epidermal Langerhans cells and platelets. CD69 is induced by antigens, mitogens or activators of PKC on the surface of T and B-lymphocytes and by interaction of IL-2 with the p75 IL-2R on the surface of NK cells. CD69 / CLEC2C involved in lymphocyte proliferation and functions as a signal transmitting receptor in lymphocytes, natural killer (NK) cells, and platelets.

CD69 References

CD69 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Mecobalamin E-0302 Approved 奇信, 曲力, 弥可保, 弥尔神, 悦敏兴, Myelogen, Naso B12, NASOCOBAL, Methycobal, RHINOCOBAL N; Peripheral Nervous System Diseases; Neuralgia; Neuritis; Amyotrophic Lateral Sclerosis Details
Triclabendazole EGA-230B; CGA-89317; NVP-EGA230 Approved Novartis Pharma Ag Egaten, Fasinex, Triclathera United States Fascioliasis s:18:"Novartis Pharma Ag"; 1989-01-01 Fascioliasis Details
Decitabine DAC; AzadC; E-7373; 5-aza-CdR; NSC-127716 Approved Eisai Co Ltd 达珂, Dacogen EU Leukemia, Myeloid s:24:"Janssen Pharmaceutica Nv"; 2006-05-02 Precursor Cell Lymphoblastic Leukemia-Lymphoma; Anemia, Sickle Cell; Carcinoma, Non-Small-Cell Lung; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Bone Marrow Diseases; Primary Myelofibrosis; Breast Neoplasms; Neuroblastoma; Leukemia, Myeloid; Myeloproliferative Disorders; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Hematologic Diseases; Leukemia; Preleukemia Details
Azacitidine NSC-102816; 5-aza-CR; CC-486; NS-17; U-18496 Approved Celgene Corp 维达莎, Vidaza, Onureg United States Leukemia, Myeloid, Acute s:12:"Celgene Corp"; 2004-05-19 Prostatic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Non-Small-Cell Lung; Melanoma; Lymphoma, Non-Hodgkin; Thyroid Neoplasms; Lymphoma; Leukemia, Myelomonocytic, Juvenile; Leukemia, Myeloid, Acute; Primary Myelofibrosis; Sarcoma; Osteosarcoma; Breast Neoplasms; Solid tumours; Multiple Myeloma; Leukemia, Myelomonocytic, Chronic; Glioblastoma; Hodgkin Disease; Small Cell Lung Carcinoma; Nasopharyngeal Neoplasms; Myelodysplastic Syndromes; Myeloproliferative Disorders; Carcinoma, Renal Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Hematologic Neoplasms; Leukemia Details
Cedazuridine/Decitabine ASTX-727; E-7727/decitabine; Decitabine/E7727 Approved Astex Pharmaceuticals Inc Inqovi United States Myelodysplastic Syndromes s:28:"Otsuka Pharmaceutical Co Ltd"; 2020-07-07 Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Myeloproliferative Disorders; Leukemia, Myeloid, Acute; Glioma Details

CD69 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Guadecitabine Sodium S-110; SGI-110; 0RB89YH367 (UNII code) Phase 3 Clinical Otsuka Holdings Co Ltd Urinary Bladder Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Urogenital Neoplasms; Lymphoma, T-Cell; Leukemia, Myeloid, Acute; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Ovarian Neoplasms; Pancreatic Neoplasms; Myeloproliferative Disorders; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Carcinoma, Renal Cell; Pheochromocytoma; Liver Neoplasms; Biliary Tract Neoplasms Details
Decitabine/Tetrahydrouridine EPI-01 Phase 1 Clinical Epicdestiny Anemia, Sickle Cell Details
EF-009 EF-009 Phase 2 Clinical Everfront Biotech Pancreatic Neoplasms Details
NTX-301 NTX-301 Phase 1 Clinical University Of Alabama At Birmingham Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details
Fluorocyclopentenylcytosine FCPEC; RX-3117; TV-1360 Phase 2 Clinical Rexahn Pharmaceuticals Pancreatic Neoplasms; Urinary Bladder Neoplasms Details
Aza-T-dCyd Aza-T-dCyd Phase 1 Clinical Southern Research Institute Neoplasms Details
Azacitidine/Cedazuridine ASTX-030 Phase 3 Clinical Otsuka Pharmaceutical Co Ltd Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details

This web search service is supported by Google Inc.

totop